In summary, accumulated evidence suggests that SGLT2 inhibitors may have considerable impact on clinical diabetes care, with the potential to markedly improve clinical outcomes in patients with T2DM, especially those at higher risk of CV events. The gene discussed is SLC5A2; the disease is diabetes mellitus.